MKGA.F Stock Overview Operates as a science and technology company in Germany. More details
Rewards Risk Analysis No risks detected for MKGA.F from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Merck KGaA Historical stock prices Current Share Price €145.41 52 Week High €200.56 52 Week Low €140.01 Beta 0.72 1 Month Change 1.47% 3 Month Change -17.36% 1 Year Change -11.04% 3 Year Change -32.37% 5 Year Change 11.12% Change since IPO 408.05%
Recent News & Updates Merck KGaA to Report Q2, 2025 Results on Aug 07, 2025
Mirror Biologics, Inc. Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer Jan 08
Merck KGaA Launches Beta Version of M-Trust, Secure Cyber-Physical Trust Platform Jan 06
Merck KGaA (XTRA:MRK) signed a definitive agreement to acquire HUB Organoids B.V. Dec 18
Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025 Nov 18
Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib Nov 12 See more updates Merck KGaA to Report Q2, 2025 Results on Aug 07, 2025
Mirror Biologics, Inc. Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer Jan 08
Merck KGaA Launches Beta Version of M-Trust, Secure Cyber-Physical Trust Platform Jan 06
Merck KGaA (XTRA:MRK) signed a definitive agreement to acquire HUB Organoids B.V. Dec 18
Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025 Nov 18
Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib Nov 12 Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million. Oct 31
Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG) Aug 29 Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS. Jul 19
Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS. Jul 18
Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer Jun 25
Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment Jun 05
Merck KGaA, Annual General Meeting, Apr 25, 2025 May 01 Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer Apr 03
Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis Dec 06 Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis Dec 05
Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024 Oct 21
Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease Oct 18
Merck KGaA, Annual General Meeting, Apr 26, 2024 Jul 08
Merck Announces CFO Changes May 09
Merck Reportedly to Put Pigments Unit Up for Sale Again Nov 19
MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023 Nov 13
MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022 Nov 12
Gerresheimer and Merck Transform Primary Packaging into Digital Twins Oct 28 MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022
Merck Launches New, High-Purity Synthetic Cholesterol Product May 27
Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021 May 05
Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer Mar 16
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study Mar 11
Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines Mar 04 Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib Feb 24
MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021 Feb 18
4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Feb 09
Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare Feb 05
MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2020 Results on Mar 04, 2021 Jan 28 MERCK Kommanditgesellschaft auf Aktien to Discontinue Bintrafusp Alfa Clinical Trial (INTR@PID Lung 037)
Merck KGaA, Darmstadt, Germany to Deploy Insilico Medicine's Chemistry42 AI Platform for Generative Chemistry Nov 19
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics Nov 10
Iktos Announces Additional Collaboration with Merck KGaA, Darmstadt, Germany in AI for New Drug Design Nov 06
Merck KGaA Announces Executive Changes Oct 16
LycoRed Natural Products Industries Ltd. acquired Nutriblend Ltd. from Merck KGaA. Sep 26
Rakuten Medical Enters into Partnership with Merck Sep 24
MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2021 Results on Aug 05, 2021 Aug 08 Shareholder Returns MKGA.F US Pharmaceuticals US Market 7D -1.5% -3.5% 3.1% 1Y -11.0% 0.2% 23.7%
See full shareholder returns
Return vs Market: MKGA.F underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is MKGA.F's price volatile compared to industry and market? MKGA.F volatility MKGA.F Average Weekly Movement 5.0% Pharmaceuticals Industry Average Movement 10.7% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: MKGA.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MKGA.F's weekly volatility (5%) has been stable over the past year.
About the Company Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Show more Merck KGaA Fundamentals Summary How do Merck KGaA's earnings and revenue compare to its market cap? MKGA.F fundamental statistics Market cap US$65.35b Earnings (TTM ) US$2.81b Revenue (TTM ) US$21.84b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MKGA.F income statement (TTM ) Revenue €20.96b Cost of Revenue €8.64b Gross Profit €12.33b Other Expenses €9.63b Earnings €2.70b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
Earnings per share (EPS) 6.20 Gross Margin 58.80% Net Profit Margin 12.86% Debt/Equity Ratio 37.8%
How did MKGA.F perform over the long term?
See historical performance and comparison Dividends
1.5% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 01:21 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Merck KGaA is covered by 60 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Martin Schnee AlphaValue Gerhard Schwarz Baader Helvea Equity Research Odile Rundquist Baader Helvea Equity Research
Show 57 more analysts 
